Kura Oncology Q4 2023 GAAP EPS $(0.55) Misses $(0.54) Estimate
Portfolio Pulse from Benzinga Newsdesk
Kura Oncology reported Q4 2023 GAAP EPS of $(0.55), missing the $(0.54) estimate by 1.85% and marking a 12.24% increase in losses from the same period last year.
February 27, 2024 | 9:26 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Kura Oncology's Q4 2023 earnings missed estimates with a GAAP EPS of $(0.55), a 12.24% increase in losses from the same period last year.
Missing the earnings estimate and reporting increased losses compared to the previous year are typically seen as negative indicators for a company's financial health and can lead to a decrease in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100